Jim Cramer Stands by Eli Lilly After Novo Nordisk GLP-1 Lawsuit
CNBC's Jim Cramer reaffirmed support for Eli Lilly during the Investing Club's Morning Meeting on July 21, 2026, despite a lawsuit from rival Novo Nordisk. Novo alleged Lilly's GLP-1 drug ads mislead consumers about superior efficacy, citing outdated comparisons before a higher Wegovy dose was approved. Cramer and portfolio director Jeff Marks dismissed the lawsuit as a 'nothing burger,' focusing on Lilly's strong injectable business outside the U.S. and its oral obesity pill Foundayo. The broader market rose, led by chipmakers like Intel, which surged 7% after landing Fortinet as its first named customer for third-party manufacturing. Salesforce was downgraded by Morgan Stanley, while Microsoft retained a buy rating despite concerns over its OpenAI relationship and Xbox headwinds. Other stocks discussed included 3M, General Motors, Danaher, Halliburton, and D.R. Horton.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection